BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34650810)

  • 1. Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report.
    Baik H; Lee HJ; Park J; Park HY; Park J; Lee S; Bae KB
    Mol Clin Oncol; 2021 Nov; 15(5):243. PubMed ID: 34650810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping.
    Lu CY; Yeh YS; Huang CW; Ma CJ; Yu FJ; Wang JY
    Onco Targets Ther; 2014; 7():2143-6. PubMed ID: 25473295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
    Kikuchi K; Ogawa M; Sasaki A
    J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
    Tai CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Chao Y; Teng HW
    Am J Clin Oncol; 2020 Jan; 43(1):28-34. PubMed ID: 31693507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival with Regorafenib in
    Amram ML; Montet X; Roth AD
    Case Rep Oncol; 2017; 10(3):1029-1034. PubMed ID: 29279709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response].
    Nemecek R; Vyzula R
    Klin Onkol; 2011; 24(6):465-9. PubMed ID: 22257237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.
    Kim ST; Kim HK; Lee J; Park SH; Lim HY; Park YS; Kang WK; Park JO
    J Cancer; 2018; 9(10):1791-1796. PubMed ID: 29805705
    [No Abstract]   [Full Text] [Related]  

  • 15. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review.
    Reddy TP; Khan U; Burns EA; Abdelrahim M
    World J Clin Oncol; 2020 Nov; 11(11):959-967. PubMed ID: 33312889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report.
    Yunoki K; Yano T; Yoshimitsu M; Oshita K; Kubota T; Ishida M; Satoh D; Choda Y; Nakano K; Shirakawa Y; Matsukawa H; Idani H; Shiozaki S; Okajima M
    Surg Case Rep; 2021 Aug; 7(1):185. PubMed ID: 34406516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer.
    Takeshita N; Fukunaga T; Kimura M; Sugamoto Y; Tasaki K; Hoshino I; Ota T; Maruyama T; Tamachi T; Hosokawa T; Asai Y; Matsubara H
    World J Gastroenterol; 2015 Nov; 21(44):12722-8. PubMed ID: 26640350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab.
    Yoshida T; Miki H; Satake H; Kobayashi T; Matsumi Y; Hamada M; Boku S; Shibata N; Ishida M; Sekimoto M
    Case Rep Oncol; 2021; 14(3):1497-1504. PubMed ID: 34899242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.